Completed Clinical Trials

Bortezomib in Treating Patients With Malignant Pleural Mesothelioma

By April 24, 2017 No Comments

Condition

Malignant Mesothelioma

Estimated Enrollment: 33

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: 05-10 ICORG|ICORG-05-10|EUDRACT-2005-004420-39|EU-20748

Study First Received: August 8, 2007

Last Updated: December 30, 2014

Estimated Primary Completion Date: December 2009

 

Primary Outcome Measures:

Objective tumor response rate (complete response or partial response) as assessed by modified RECIST criteria|Time to disease progression|Overall survival|Safety|Quality of life

Sponsors and Collaborators:

Cancer Trials Ireland

Website Link: https://ClinicalTrials.gov/show/NCT00513877

Leave a Reply

Call Now ButtonCall Now